Quick Answer
Valerian Sleep Latency Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Medicinal plants and their preparations have gained increased interest—not only because of their use in traditional medicine, but also owing to growing preclinical and clinical data indicating their potential efficacy within the CNS [,].
Key Takeaways
- 01Medicinal plants and their preparations have gained increased interest—not only because of their use in traditional medicine, but also owing to growing preclinical and clinical data indicating their potential efficacy within the CNS [,]. [Mielczarek Lidia (2026)]
- 02Potential clinical benefits are included, while the risk of adverse effects is also described, and legal regulations surrounding the possibility of using the raw materials as dietary supplements are mentioned, along with safety assessments at the European level. [Mielczarek Lidia (2026)]
- 03Its aim is to summarize and critically discuss the clinical, toxicological, and regulatory evidence regarding,, andin disorders of the central nervous system, rather than to answer a single predefined question through a systematic protocol. [Mielczarek Lidia (2026)]
- 04biloba Neurological and neuropsychiatric disorders (NDs), which include ADHD, Parkinson’s disease, migraine, insomnia, anxiety disorders, and dementia, are a varied group of conditions that involve the loss of neurons and worsening degeneration of various areas of the nervous system. [Mielczarek Lidia (2026)]
The current Migaku evidence database contains 2 reusable source documents for Valerian Sleep Latency Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts.
- Medicinal plants and their preparations have gained increased interest—not only because of their use in traditional medicine, but also owing to growing preclinical and clinical data indicating their potential efficacy within the CNS [,]. [Mielczarek Lidia (2026); evidence level 3]
- Potential clinical benefits are included, while the risk of adverse effects is also described, and legal regulations surrounding the possibility of using the raw materials as dietary supplements are mentioned, along with safety assessments at the European level. [Mielczarek Lidia (2026); evidence level 3]
- Its aim is to summarize and critically discuss the clinical, toxicological, and regulatory evidence regarding,, andin disorders of the central nervous system, rather than to answer a single predefined question through a systematic protocol. [Mielczarek Lidia (2026); evidence level 3]
- biloba Neurological and neuropsychiatric disorders (NDs), which include ADHD, Parkinson’s disease, migraine, insomnia, anxiety disorders, and dementia, are a varied group of conditions that involve the loss of neurons and worsening degeneration of various areas of the nervous system. [Mielczarek Lidia (2026); evidence level 3]
- Failure to meet the recommended 7-9 hours of restful sleep per night is known to increase the risk of several health conditions, reason why regular and adequate sleep should be seen as a priority instead of an unnecessary commodity easily traded as required by the commitments of our busy lives. [Conti F (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources